How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

13,956 results for

Squamous Cell Carcinoma of the Skin

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy

Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results (...) information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing

2018 Clinical Trials

122. Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03650764

2018 Clinical Trials

123. Moderately Hypofractionated Conformal Radiation Combined With Cisplatin for Esophageal Squamous Cell Carcinoma

Moderately Hypofractionated Conformal Radiation Combined With Cisplatin for Esophageal Squamous Cell Carcinoma Moderately Hypofractionated Conformal Radiation Combined With Cisplatin for Esophageal Squamous Cell Carcinoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Moderately Hypofractionated Conformal Radiation Combined With Cisplatin for Esophageal Squamous Cell Carcinoma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier

2018 Clinical Trials

124. Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study)

Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study) Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study) (ALPHA) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03695510 Recruitment Status : Not yet recruiting First Posted

2018 Clinical Trials

125. Phase II Study of Perioperative Immunotherapy in Patients With Advanced Non-Virally Associated Squamous Cell Carcinoma

basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy, in situ cervical cancer, low-grade thyroid cancer and indolent prostate cancer. Additional malignancies may be permitted after consultation with the principal investigator Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g (...) Phase II Study of Perioperative Immunotherapy in Patients With Advanced Non-Virally Associated Squamous Cell Carcinoma Phase II Study of Perioperative Immunotherapy in Patients With Advanced Non-Virally Associated Squamous Cell Carcinoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2018 Clinical Trials

126. Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma

Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety (...) and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03713372 Recruitment Status : Not yet recruiting First Posted : October 19, 2018 Last Update Posted : October 19

2018 Clinical Trials

127. Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma

Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma (OESIRI) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our

2018 Clinical Trials

128. miR-186 promotes tumor growth in cutaneous squamous cell carcinoma by inhibiting apoptotic protease activating factor-1 (Full text)

miR-186 promotes tumor growth in cutaneous squamous cell carcinoma by inhibiting apoptotic protease activating factor-1 Cutaneous squamous cell carcinoma (cSCC) accounts for 20% of non-melanoma skin cancer worldwide. MicroRNAs (miRNAs or miRs) are a subtype of non-coding RNA associated with the progression of various types of human cancer. MiR-186 has been demonstrated to act as an oncogene in human tumors. However, the role of miR-186 in cSCC remains unclear. The expression of miR-186 (...) and apoptotic protease activating factor 1 (APAF1) was examined using reverse transcription-quantitative polymerase chain reaction, western blotting and immunofluorescence. The correlation between miR-186 and APAF1 was determined using a dual-luciferase assay. Mimics or inhibitors of miR-186 were transfected into A-431 cells to establish cell lines with overexpressed or knocked-down miR-186, respectively. EdU staining and colony formation assays were performed to detect cell proliferation. Transwell

2018 Experimental and therapeutic medicine PubMed abstract

129. Squamous Cell Carcinomas in Two Cases of Nail Lichen Planus: Is There a Real Association? (Full text)

Squamous Cell Carcinomas in Two Cases of Nail Lichen Planus: Is There a Real Association? Lichen planus (LP) is a chronic inflammatory disease that affects the skin and oral mucosa. Although its etiology is unknown, its potential for cancerization has been confirmed. We herein report the cases of a brother and sister, both with a 15-year history of nail lichen planus of the fingers and toes, who developed squamous cell carcinomas of the nail bed and matrix. This article shows the potential

2018 Dermatology and therapy PubMed abstract

130. A giant cutaneous squamous cell carcinoma of the neck (Full text)

101517926 IM Aged Carcinoma, Squamous Cell diagnosis pathology Fatal Outcome Head and Neck Neoplasms diagnosis pathology Humans Male Skin Neoplasms diagnosis pathology Squamous Cell Carcinoma of Head and Neck Skin chemotherapy squamous cell carcinoma 2018 01 26 2018 05 01 2018 9 1 6 0 2018 9 1 6 0 2018 10 3 6 0 epublish 30167050 10.11604/pamj.2018.30.22.14984 PAMJ-30-22 PMC6110546 (...) A giant cutaneous squamous cell carcinoma of the neck 30167050 2018 10 01 2019 02 21 1937-8688 30 2018 The Pan African medical journal Pan Afr Med J A giant cutaneous squamous cell carcinoma of the neck. 22 10.11604/pamj.2018.30.22.14984 Bazine Aziz A Medical Oncology Department, Military Hospital Moulay Ismaïl, Meknès, Morocco. Fetohi Mohamed M Medical Oncology Department, Military Hospital Moulay Ismaïl, Meknès, Morocco. eng Case Reports Journal Article 2018 05 15 Uganda Pan Afr Med J

2018 The Pan African medical journal PubMed abstract

131. Effective treatment of a platinum-resistant cutaneous squamous cell carcinoma case by EGFR pathway inhibition (Full text)

Effective treatment of a platinum-resistant cutaneous squamous cell carcinoma case by EGFR pathway inhibition Cutaneous squamous cell carcinoma (cSCC) is the second most common type of non-melanoma skin cancer. Platinum-based regimens have been an integral part of palliative care for patients with locally advanced or metastatic disease. There is no evidence of efficacy for later lines of chemotherapy and no targeted therapy has been introduced as 'standard of care'. Here we report on the case (...) of an elderly cSCC patient, resistant to conventional therapy, however successfully treated with anti-epidermal growth factor receptor (EGFR) agent (Cetuximab) in addition to a daily dose of Curcumin phospholipid. The patient responded to treatment and experienced no recurrence for 11 months with only minor skin-related toxicity. To our knowledge, this is the first report of clinical evidence that an anti EGFR targeted therapy with a daily oral dose of Curcumin phospholipid is well tolerated and results

2018 Molecular and clinical oncology PubMed abstract

132. Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B (Full text)

Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B Notch 1/2 genes play tumor-suppressing functions in squamous cell carcinoma (SCC), a very common malignancy in skin and internal organs. In contrast with Notch, we show that the transcription factor CSL (also known as RBP-Jκ), a key effector of canonical Notch signaling endowed with intrinsic transcription-repressive functions, plays a tumor-promoting function in SCC development. Expression of this gene (...) decreased in upper epidermal layers and human keratinocytes (HKCs) undergoing differentiation, while it increased in premalignant and malignant SCC lesions from skin, head/neck, and lung. Increased CSL levels enhanced the proliferative potential of HKCs and SCC cells, while silencing of CSL induced growth arrest and apoptosis. In vivo, SCC cells with increased CSL levels gave rise to rapidly expanding tumors, while cells with silenced CSL formed smaller and more differentiated tumors with enhanced

2018 The Journal of clinical investigation PubMed abstract

133. A Natural History of Actinic Keratosis and Cutaneous Squamous Cell Carcinoma Microbiomes (Full text)

A Natural History of Actinic Keratosis and Cutaneous Squamous Cell Carcinoma Microbiomes Cutaneous squamous cell carcinoma (SCC) is the second-most-common cancer in Australia. The majority of SCCs progress from premalignant actinic keratosis (AK) lesions that form on chronically sun-exposed skin. The role of skin microbiota in this progression is not well understood; therefore, we performed a longitudinal microbiome analysis of AKs and SCCs using a cohort of 13 SCC-prone immunocompetent men (...) , suggesting their specific involvement with AK-to-SCC progression. If a causative link exists between certain S. aureus-like OTUs and SCC etiology, therapeutic approaches specifically targeting these bacteria could be used to reduce SCC.IMPORTANCE Actinic keratosis (AK) and cutaneous squamous cell carcinoma (SCC) are two of the most common dermatologic conditions in Western countries and cause substantial morbidity worldwide. The role of human papillomaviruses under these conditions has been well studied

2018 mBio PubMed abstract

134. Successful development of squamous cell carcinoma and hyperplasia in RGEN-mediated p27 KO mice after the treatment of DMBA and TPA (Full text)

) and 12-O-tetradecanoylphorbol-13-acetate (TPA)(DT) for 5 months. The target region (544~571 nt) in exon I of the p27 gene was successfully disrupted in p27 (IΔ) KO mice using the RGEN-induced non-homologous end joining (NHEJ) technique. After DT exposure for 5 months, a few solid tumors (identified as squamous cell carcinoma) developed on the surface of back skin of DT-treated p27 (IΔ) KO mice. Also, squamous cell hyperplasia with chronic inflammation was detected in the skin dermis of DT-treated p27 (...) (IΔ) KO mice, while the Vehicle+p27 (IΔ) KO mice and WT mice maintained their normal histological skin structure. A significant increase was observed in the expression levels of tumor suppressor protein (p53), apoptotic proteins (Bax, Bcl-2 and Caspase-3) and cell-cycle regulator proteins (Cyclin D1, CDK2 and CDK4) in the skin of DT-treated p27 (IΔ) KO mice, although their enhancement ratio was varied. Taken together, the results of the present study suggest that squamous cell carcinoma

2018 Laboratory animal research PubMed abstract

135. Cutaneous squamous cell carcinoma with subtle perineural invasion detected with cytokeratin and epithelial membrane antigen immunohistochemistry (Full text)

squamous cell carcinoma immunohistochemistry perineural invasion radiation therapy skin cancer squamous cell carcinoma 2018 10 16 6 0 2018 10 16 6 0 2018 10 16 6 1 epublish 30320199 10.1016/j.jdcr.2018.09.002 S2352-5126(18)30247-9 PMC6180242 J Am Acad Dermatol. 2018 Feb;78(2):237-247 29332704 Australas J Dermatol. 2014 May;55(2):107-10 24372092 Oral Oncol. 2012 Oct;48(10):918-922 22425152 JAAD Case Rep. 2016 Aug 24;2(4):346-9 27617283 Cancer. 2007 Mar 15;109(6):1053-9 17279578 J Cutan Pathol. 2008 Apr (...) Cutaneous squamous cell carcinoma with subtle perineural invasion detected with cytokeratin and epithelial membrane antigen immunohistochemistry 30320199 2019 02 26 2352-5126 4 9 2018 Oct JAAD case reports JAAD Case Rep Cutaneous squamous cell carcinoma with subtle perineural invasion detected with cytokeratin and epithelial membrane antigen immunohistochemistry. 934-937 10.1016/j.jdcr.2018.09.002 Lee Alison K AK Department of Dermatology, Yale School of Medicine, New Haven, Connecticut. Yoo

2018 JAAD Case Reports PubMed abstract

136. WW domain-containing E3 ubiquitin protein ligase 1 depletion evokes antitumor effect in cutaneous squamous cell carcinoma by inhibiting signal transducer and activator of transcription 3 signaling pathway (Full text)

WW domain-containing E3 ubiquitin protein ligase 1 depletion evokes antitumor effect in cutaneous squamous cell carcinoma by inhibiting signal transducer and activator of transcription 3 signaling pathway Objectives WW domain-containing E3 ubiquitin protein ligase 1 (WWP1) has been implicated in tumor progression. We aimed to investigate the role of WWP1 in cutaneous squamous cell carcinoma (CSCC). Methods WWP1 gene and protein levels were detected using semi-quantitative reverse transcription (...) -polymerase chain reaction, immunohistochemistry and western blotting. The effects of WWP1 on cell cycle, apoptosis, cell migration and invasion were examined by flow cytometry, wound healing and Transwell assays, respectively. The antitumor efficacy of WWP1 small interfering RNA was determined in CSCC tumor xenografts in mice. Results WWP1 expression was significantly higher in CSCC tissues and cells than in normal skin and cells, respectively. WWP1 expression was significantly associated

2018 The Journal of international medical research PubMed abstract

137. Recent advances in field cancerization and management of multiple cutaneous squamous cell carcinomas (Full text)

Recent advances in field cancerization and management of multiple cutaneous squamous cell carcinomas Cutaneous squamous cell carcinoma (SCC) is among the most common cancers in humans, and many patients with SCC will develop multiple tumors within their lifetime. The field cancerization concept, originally proposed over 60 years ago, hypothesized that multiple primary cancers may arise simultaneously and coexist with subclinical precursor lesions within a defined field. Genetic sequencing (...) of SCC and precursor lesions has identified what may be the earliest clonal proliferations in SCC development and confirmed that field cancerization in the skin is mediated by ultraviolet radiation. For patients with multiple SCCs and severe actinic damage, treatment of precursor lesions within a cancerized field can decrease the risk of subsequent cancer development. Sunblock is an effective intervention for field cancerization, even in patients with established disease. There is now direct evidence

2018 F1000Research PubMed abstract

138. Gene expression imputation identifies candidate genes and susceptibility loci associated with cutaneous squamous cell carcinoma (Full text)

Gene expression imputation identifies candidate genes and susceptibility loci associated with cutaneous squamous cell carcinoma Cutaneous squamous cell carcinoma (cSCC) is a common skin cancer with genetic susceptibility loci identified in recent genome-wide association studies (GWAS). Transcriptome-wide association studies (TWAS) using imputed gene expression levels can identify additional gene-level associations. Here we impute gene expression levels in 6891 cSCC cases and 54,566 controls

2018 Nature communications PubMed abstract

139. Squamous Cell Carcinoma Arising within Verruca Vulgaris on the Nipple (Full text)

Squamous Cell Carcinoma Arising within Verruca Vulgaris on the Nipple Cutaneous squamous cell carcinoma (SCC) is a common form of skin cancer and often appears as a hard, scaly lump that occasionally ulcerates. It is usually associated with cumulative exposure to ultraviolet light, although prior scarring, chronic wounds, exposure to radiation, HPV infection, and immunosuppression are also associated risk factors. Primary SCC of the nipple is very rare and only a few cases have been reported

2018 Case reports in dermatological medicine PubMed abstract

140. Advanced squamous-cell carcinoma of the lower lip (Full text)

Beneficência, Ribeirão Preto, São Paulo, Brazil. eng Case Reports Journal Article 2018 06 20 Uganda Pan Afr Med J 101517926 IM Adult Carcinoma, Squamous Cell diagnosis pathology therapy Fatal Outcome Humans Lip Neoplasms diagnosis pathology therapy Male Prognosis Squamous Cell carcinoma neglected diseases skin neoplasms 2017 11 09 2018 05 19 2018 10 31 6 0 2018 10 31 6 0 2018 12 13 6 0 epublish 30374394 10.11604/pamj.2018.30.148.14352 PAMJ-30-148 PMC6201625 (...) Advanced squamous-cell carcinoma of the lower lip 30374394 2018 12 12 2018 12 12 1937-8688 30 2018 The Pan African medical journal Pan Afr Med J Advanced squamous-cell carcinoma of the lower lip. 148 10.11604/pamj.2018.30.148.14352 Filho Fred Bernardes FB Dermatology Division, Department of Medical Clinics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil. Grupioni Priscila Vinhal PV Department of Oncology, Hospital Imaculada Conceição da Sociedade Portuguesa de

2018 The Pan African medical journal PubMed abstract

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>